Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Opioid

or [[:Category:Tryptamines|Tryptamine]]

or dissociative

Use the filters below to narrow your results.

Codeine (2)

None (30) · (multiple, generic dominant) (1) · Alfenta (1) · COMP360 (Compass Pathways, investigational synthesized clinical formulation) (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · DXM (1) · DXO (1) · Heroin (1) · Krokodil (1) · Nubain (1) · Nucynta (1) · O-DSMT (1) · Opana (1) · Spravato (1) · Stablon (1) · Stadol (1) · Suboxone (1) · Sufenta (1) · Talwin (1) · Ultiva (1) · Vicodin (1)

Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · NMDA antagonist (3) · NMDA antagonist; sigma receptor agonist (2)

Other values:

None (51) · (investigational) '"`UNIQ--vote-000000EF-QINU`"', '"`UNIQ--vote-000000F0-QINU`"', '"`UNIQ--vote-000000F1-QINU`"', '"`UNIQ--vote-000000F2-QINU`"', '"`UNIQ--vote-000000F3-QINU`"' (1) · Mild to moderate pain; cough suppression (low-dose). (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)

None (51) · Adult: 15–60 mg every 4 hours as needed. (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) · Modern clinical-trial standard: 25 mg synthesized psilocybin, single oral dose with psychological support (1)

None (51) · 28 mg/device (each dose uses 2 devices) (1) · Synthesized psilocybin capsules (COMP360 and other investigational formulations); dried whole [[Psilocybe|Psilocybe]] mushrooms (variable potency, no legal supply chain in most jurisdictions); psilocybin truffles (Psilocybe sclerotia, legal in the Netherlands) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (51) · 360 mg/day (1) · 84 mg per session (1) · Not FDA-approved; clinical-trial protocols use up to 30 mg in adult investigational dosing (1)

None (51) · Intranasal (under direct medical supervision) (1) · Oral (1) · PO (only formulation marketed in the US). (1)

None (51) · 20-45 min subjective onset; psilocin formation from psilocybin requires intestinal and hepatic alkaline phosphatase (1) · 30–60 min (PO) (1) · Within hours of first administration (1)

None (50) · 4-6 hours (1) · 4–6 hours (1) · About 20 minutes (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

None (50) · 2.5–3 hours (1) · 9–12 minutes (intravenous) (1) · Psilocin: ~2-3 h; psilocybin itself is a prodrug, dephosphorylated within minutes of absorption (1) · ~7-12 hours (1)

None (51) · Oral bioavailability of psilocin from administered psilocybin approximately 50% (1) · ~48% intranasal (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (51) · Avoid; may cause fetal harm (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Not studied in human pregnancy; no approved clinical use in any population (1)

None (51) · Rx, Schedule III (US). REMS program required. (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)

Showing below up to 54 results in range #1 to #54.

2

2-FDCK

3

4

4-MeO-PCP

7

7-Hydroxymitragynine

A

B

C

D

E

F

Fentanyl

H

I

Ibogaine

K

Kratom

L

Levorphanol

M

N

O

P

R

Remifentanil

S

T

U

U-47700

X

Xenon

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"